Foley & Lardner LLP represented TCGX as a lead investor in the oversubscribed $200 million Series C financing for ADARx, a leader in next generation RNA Therapeutics. TCGX led the round jointly with Bain Capital Life Sciences.
ADARx is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx has developed proprietary RNA delivery platforms and technology for silencing or editing target mRNA and has a growing pipeline of RNA therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiovascular, complement-mediated, and central nervous system.
Funding will be used to further advance ADARx clinical programs including ADX-324 and ADX-038. ADX-324 represents an innovative approach for the treatment of hereditary angioedema, a rare genetic disease that causes painful, rapid, and potentially life-threatening swelling attacks, while ADX-038 is being developed for the treatment of multiple complement mediated diseases. The funding will also support advancement of a pipeline of innovative mRNA silencing or editing candidates for the treatment of a broad range of diseases.
The Foley team was led by partner Louis Lehot and included partners Rishi Sodhi and Lyman Thai and associate Ethan Floyd.
Foley’s Venture & Growth Capital attorneys understand the complex and diverse needs of both venture funds and their portfolio companies and offer a broad range of services at each stage of development. The attorneys have insight into the unique needs of high-growth companies operating in the technology, life science, smart manufacturing, and clean energy sectors.
폴리생명과학팀은 기업, 의료, 규제, 지식재산권 분야 변호사들로 구성되어 있으며, 포괄적인 접근 방식으로 생명과학 산업의 신생 기업과 기존 기업이 변동하는 글로벌 금융 시장, 급변하는 지식재산권 환경, 시장에 출시하는 제품에 영향을 미칠 수 있는 규제 장벽을 헤쳐나가도록 지원합니다. 수십 년간 당사 변호사들은 생명과학 기업들이 발전의 모든 단계에서 업계에 발자취를 남길 수 있도록 협력해 왔습니다.
